IL22 and colitis: Administration of αThy‐1 enhanced the colitis, which was alleviated by IL‐22 treatment, whereas Reg3β administration improved the DSS colitis in these mice by increasing the IL‐22 mucosal levels through recruitment of IL‐22‐producing neutrophils.91 Interestingly, a mutation in IL‐23R is associated with a reduced likelihood of Crohn's disease.